[5][6] HDAC6 has emerged as a highly promising candidate to selectively inhibit as a therapeutic strategy to combat several types of cancer and neurodegenerative disorders.

[7] Histones play a critical role in transcriptional regulation, cell cycle progression, and developmental events.

[7] Selective inhibition of HDAC6 as a strategy to treat cancers is however also subject of debate, since some HDAC6 inhibitors exhibited anti-tumor activity in vitro and in vivo only when administered in high concentrations, which also produced off-target effects.

The findings suggest that further study is needed to clarify data on anti-cancer effects of selective HDAC6 inhibitors.

[12] This article incorporates text from the United States National Library of Medicine, which is in the public domain.